Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02823964 · ClinicalTrials.gov registry record · Phase 4
EASY: Extended Access to Sollpura Over Years
A Phase 4 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT02823964 is a Phase 4 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT02823964, a Phase 4 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be formulated without enteric coating for administration either as a capsule or as a dosing solution dissolved in water or juice.
Interventions
- DRUG Liprotamase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02823964
The ClinicalTrials.gov registry entry for NCT02823964 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liprotamase is the first listed.
NCT02823964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02823964 about?
NCT02823964 is a clinical study titled "EASY: Extended Access to Sollpura Over Years". Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be formulated without enteric coating for administration either as a capsule or as a dosing solution dissolved in water or juice.
What is the current status of trial NCT02823964?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2016-09. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02823964?
The interventions under investigation include: Liprotamase (DRUG).
Who is sponsoring clinical trial NCT02823964?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.